Connect your AI

iRadimed IRMD 2031

2031 at other companies

ICU MedicalICUI

——

MedtronicMDT

——

AbbottABT

——

Other financials

Income statement

Revenue$22.0M+12.6%

Gross profit$16.8M+13.3%

Operating income$7.2M+33.2%

Net income$5.8M+24.1%

EPS (diluted)$0.45+21.6%

Balance sheet

Cash & equivalents$56.4M+12.0%

Total debt$59.2K-96.9%

Total equity$98.5M+9.4%

Total assets$114.4M+12.4%

Cash flow

Operating cash flow$8.3M+93.2%

CapEx$403.0K-89.1%

Free cash flow$7.9M+1,226%

Valuation

Market cap$1.21B+63.4%

P/E51.3×+13.8×

P/S14×+4.2×

Profitability

Gross margin76.8%-0.1pp

Operating margin32.4%+2.3pp

Net margin27.4%+1.0pp

FCF margin28.4%+8.9pp

Returns & leverage

Return on equity25%+1.2pp

Debt / equity0×0.0×

Current ratio7.1×-1.7×

Where this comes from

Reported directly by iRadimed in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.

The official record: iRadimed’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRadimed's 2031.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is iRadimed's 2031?: iRadimed (IRMD) reported 2031 of $225K in Q1 2026.